Combination therapies are transforming the malignant melanoma treatment landscape, raising the efficacy bar for emerging therapies. However, combination therapies have increased the cost of…
This three-wave syndicated report series tracks the introduction of Darzalex, a human anti-CD38 MAb, and Empliciti, a humanized anti-SLAMF7 MAb. The FDA approved these agents in November 2015 for…
The first-line mCRPC market is highly competitive due to the availability of several efficacious and safe hormonal agents that are well entrenched in this indication. Although these therapies have…
The multiple myeloma market is becoming increasingly crowded. In 2015, several new, high-priced therapies have been approved for in the treatment of multiple myeloma, making this lucrative market…
Owing to the large size of the advanced/metastatic, HR-positive/HER2-negative breast cancer market, as well as the long durations of treatment typically associated with treating these patients,…
Owing to the large size of the advanced/metastatic, HR-positive/HER2-negative breast cancer market, as well as the long durations of treatment typically associated with treating these patients,…
LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Lemtrada, a potent, intravenous disease-modifying therapy (DMT) approved to treat…
Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are chronic and, in many cases, debilitating diseases requiring lifelong treatment. Costs associated with biologic treatment for RA…
Type 2 diabetes and obesity are chronic diseases that affect millions of Americans and represent a costly expense for the nation’s healthcare payers. In the effort to manage quality and costs…
Emerging Therapies: Nucala (US) is a three-wave, syndicated, detailed, expanded analysis that tracks the introduction of Nucala, the first IL-5 inhibitor approved to treat eosinophilic asthma. The…
“LaunchTrends®: Inflectra/Remsima (Wave 2) is the second in a series of syndicated reports designed to track physician perception and uptake of Hospira’s Inflectra and Mundipharma’s Remsima,…
Introduction Rheumatoid arthritis (RA) represents a lucrative market, particularly because of the entrenched positioning of biologics in the treatment algorithm. A number of RA biologics have been…
Acute lymphoblastic leukemia (ALL), also known as acute lymphoid leukemia or cancer of the white blood cells, develops from lymphocytes overproduced in the bone marrow that spread to other sites…
Last Updated 30 December 2015 In late age-related macular degeneration (AMD), vision deficits are noticeable, often debilitating, and can be a precursor to blindness. The availability of vascular…
Hepatitis C virus (HCV) is the leading cause of end-stage liver disease and hepatocellular carcinoma in China. The prevalence of this chronic disease remains high owing to the presence of a large…
